Gene: CSNK1E

1454
CKIe|CKIepsilon|HCKIE
casein kinase 1 epsilon
protein-coding
22q13.1
Ensembl:ENSG00000213923 MIM:600863 Vega:OTTHUMG00000151135 UniprotKB:P49674
NG_016707.1
PubMed
0   ANCO-SNPs
CD|ND
3   
5.136e-1 (AD)  6.447e-1 (ND)   (Frontal_Cortex)
1.063e-1 (AD)  2.699e-1 (ND)

DNA Methylation

Probe Locus(GRCh37) Gene Region p-val Trait PubMed ID
cg19781870chr22:38714285CSNK1EPromoter1.881e-4Alcohol use disorders26763658
cg04728789chr22:38711154CSNK1EPromoter6.229e-4Alcohol use disorders26763658

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
ADD10.938
HGS0.938
RAB1B0.933
CSNK1D0.929
AP3D10.926
GRINA0.924
DVL30.924
ILF30.924
KHSRP0.921
SH2B10.921

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
OR4F5-0.811
OR4F29-0.778
MTRNR2L9-0.295
MTRNR2L6-0.288
MTRNR2L10-0.275
GZMK-0.256
KLRB1-0.249
TTLL10-AS1-0.248
KCNJ15-0.244
CD48-0.241

Drugs/Compounds

ID Drug Name Drug Type CAS Num Status Role
DB06195SeliciclibSmall Molecule186692-46-6InvestigationalTarget
ID Drug Name Action PubMed
C0164032,4-dinitrotoluene"2,4-dinitrotoluene affects the expression of CSNK1E mRNA"21346803
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CSNK1E mRNA"27188386
C0352074-amino-2,6-dinitrotoluene"4-amino-2,6-dinitrotoluene affects the expression of CSNK1E mRNA"21346803
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CSNK1E mRNA"27188386
C5585299-(6-aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo(h)(1,6)naphthyridin-2(1H)-one"9-(6-aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo(h)(1,6)naphthyridin-2(1H)-one binds to CSNK1E protein"21322566
D000082AcetaminophenAcetaminophen affects the expression of CSNK1E mRNA17562736
D020106AcrylamideAcrylamide results in decreased expression of CSNK1E mRNA28959563
D016604Aflatoxin B1Aflatoxin B1 results in increased expression of CSNK1E mRNA22100608
D016604Aflatoxin B1Aflatoxin B1 results in increased expression of CSNK1E mRNA19770486
D000643Ammonium ChlorideAmmonium Chloride affects the expression of CSNK1E mRNA16483693
D000661AmphetamineCSNK1E gene polymorphism affects the susceptibility to Amphetamine16237383
D000661AmphetamineCSNK1E protein results in increased susceptibility to Amphetamine16237383
D018501Antirheumatic AgentsAntirheumatic Agents results in increased expression of CSNK1E mRNA24449571
D001554BenzeneBenzene results in decreased expression of CSNK1E mRNA19162166
D0151237,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide"7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in decreased expression of CSNK1E mRNA"19150397
D004958EstradiolEstradiol affects the expression of CSNK1E mRNA22574217
C006780bisphenol Abisphenol A affects the expression of CSNK1E mRNA21786754
C006780bisphenol Abisphenol A results in decreased expression of CSNK1E mRNA20678512|2927551
C006780bisphenol Abisphenol A affects the expression of CSNK1E mRNA25181051
C005961bis(tri-n-butyltin)oxidebis(tri-n-butyltin)oxide results in increased expression of CSNK1E mRNA17553608
D002251Carbon TetrachlorideCarbon Tetrachloride results in decreased expression of CSNK1E mRNA17484886
D003300Copper[Disulfiram binds to Copper] which results in increased expression of CSNK1E mRNA24690739
D016572CyclosporineCyclosporine results in increased expression of CSNK1E mRNA25562108
D003993Dibutyl PhthalateDibutyl Phthalate results in increased expression of CSNK1E mRNA21266533
D004026DieldrinDieldrin results in decreased expression of CSNK1E mRNA20438755
D004041Dietary Fats[Dietary Fats co-treated with Dietary Sucrose] results in decreased expression of CSNK1E mRNA28433925
D004041Dietary FatsDietary Fats results in increased expression of CSNK1E mRNA18042831
D019422Dietary Sucrose[Dietary Fats co-treated with Dietary Sucrose] results in decreased expression of CSNK1E mRNA28433925
D004221Disulfiram[Disulfiram binds to Copper] which results in increased expression of CSNK1E mRNA24690739
C000499ferric oxideferric oxide analog results in increased expression of CSNK1E mRNA25086211
D005472FluorouracilFluorouracil affects the expression of CSNK1E mRNA16584549
D006861Hydrogen Peroxide[Hydrogen Peroxide co-treated with Theophylline] results in decreased expression of CSNK1E protein18951874
C411652IC 261IC 261 results in increased expression of CSNK1E protein16027726
C492448ICG 001ICG 001 results in increased expression of CSNK1E mRNA26191083
D015759Ionomycin[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CSNK1E mRNA25613284
C410337K 7174K 7174 results in increased expression of CSNK1E mRNA24086573
D007854LeadLead affects the phosphorylation of CSNK1E protein22387731
D008767Methylmercury CompoundsMethylmercury Compounds results in decreased expression of CSNK1E protein19000711
D037742Nanotubes, Carbon"Nanotubes, Carbon analog results in decreased expression of CSNK1E mRNA"25554681
D037742Nanotubes, Carbon"Nanotubes, Carbon results in decreased expression of CSNK1E mRNA"25554681
C017096n-butoxyethanoln-butoxyethanol results in increased expression of CSNK1E mRNA19812364
D009534NiclosamideNiclosamide results in increased expression of CSNK1E mRNA22576131
C570897NSC668394NSC668394 results in increased expression of CSNK1E mRNA27137931
C042670N-vinyl-2-pyrrolidinone[N-vinyl-2-pyrrolidinone binds to N-vinyl-2-pyrrolidinone] which results in increased expression of CSNK1E mRNA22037397
D000073878Palm OilPalm Oil results in increased expression of CSNK1E mRNA18042831
D010634PhenobarbitalPhenobarbital affects the expression of CSNK1E mRNA19159669
D010634PhenobarbitalNR1I3 protein affects the reaction [Phenobarbital results in increased expression of CSNK1E mRNA]19482888
D010634PhenobarbitalPhenobarbital results in increased expression of CSNK1E mRNA19482888
C006253pirinixic acid[pirinixic acid binds to and results in increased activity of PPARA protein] which results in decreased expression of CSNK1E mRNA19710929
D011192Potassium DichromatePotassium Dichromate results in increased expression of CSNK1E protein23718831
C045362prochlorazprochloraz results in increased expression of CSNK1E mRNA21470553
C045950propiconazolepropiconazole results in increased expression of CSNK1E mRNA21278054
D012643Selenium[Selenium co-treated with Vitamin E] results in decreased expression of CSNK1E mRNA19244175
D012643SeleniumSelenium results in increased expression of CSNK1E mRNA19244175
D012715Sesame OilSesame Oil results in increased expression of CSNK1E mRNA29191790
C017947sodium arsenitesodium arsenite results in decreased expression of CSNK1E mRNA25879800
D018038Sodium SeleniteSodium Selenite results in increased expression of CSNK1E mRNA18175754
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in increased expression of CSNK1E mRNA18495758
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of CSNK1E mRNA21570461
D013755Tetradecanoylphorbol Acetate[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CSNK1E mRNA25613284
D013806Theophylline[Hydrogen Peroxide co-treated with Theophylline] results in decreased expression of CSNK1E protein18951874
D013974ThyroxineThyroxine affects the expression of CSNK1E mRNA17403546
C057693troglitazonetroglitazone results in decreased expression of CSNK1E mRNA28973697
D014520UrethaneUrethane results in increased expression of CSNK1E mRNA28818685
D014635Valproic Acid"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CSNK1E mRNA"27188386
D014635Valproic AcidValproic Acid affects the expression of CSNK1E mRNA25979313
D014635Valproic AcidValproic Acid results in decreased expression of CSNK1E mRNA26272509
D014635Valproic AcidValproic Acid results in increased expression of CSNK1E mRNA23179753
D014640VancomycinVancomycin results in decreased expression of CSNK1E mRNA18930951
D014810Vitamin E[Selenium co-treated with Vitamin E] results in decreased expression of CSNK1E mRNA19244175
C111237vorinostatvorinostat results in decreased expression of CSNK1E mRNA27188386

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0003723RNA binding-HDA22681889  
GO:0004672protein kinase activity-IDA14722104  17244647  
GO:0004672protein kinase activity-ISS-  
GO:0004674protein serine/threonine kinase activity-IBA21873635  
GO:0004674protein serine/threonine kinase activity-IDA15917222  25500533  
GO:0004674protein serine/threonine kinase activity-TAS7797465  
GO:0005515protein binding-IPI11425858  15917222  16616143  16618118  16790549  17218255  
17244647  17353931  20708156  21900206  21988832  22609948  
22682247  22939624  23109420  23413191  23455922  25241761  
25416956  25910212  26496610  
GO:0005524ATP binding-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0000086G2/M transition of mitotic cell cycle-TAS-  
GO:0006281DNA repair-TAS7797465  
GO:0006468protein phosphorylation-IDA15917222  17244647  
GO:0006468protein phosphorylation-ISS-  
GO:0006897endocytosis-IBA21873635  
GO:0007165signal transduction-TAS7797465  
GO:0010389regulation of G2/M transition of mitotic cell cycle-TAS-  
GO:0018105peptidyl-serine phosphorylation-IBA21873635  
GO:0018105peptidyl-serine phosphorylation-IDA25500533  
GO:0032091negative regulation of protein binding-IDA23109420  
GO:0032436positive regulation of proteasomal ubiquitin-dependent protein catabolic process-ISS-  
GO:0032922circadian regulation of gene expression-ISS-  
GO:0042752regulation of circadian rhythm-ISS-  
GO:0060070canonical Wnt signaling pathway-IDA14722104  
GO:0060070canonical Wnt signaling pathway-IGI12556519  
GO:0060070canonical Wnt signaling pathway-IMP14722104  
GO:0097711ciliary basal body-plasma membrane docking-TAS-  
GO:1903827regulation of cellular protein localization-IDA17244647  
GO:1905426positive regulation of Wnt-mediated midbrain dopaminergic neuron differentiation-NAS17244647  
GO:2000052positive regulation of non-canonical Wnt signaling pathway-IC17244647  
GO ID GO Term Qualifier Evidence PubMed
GO:0005634nucleus-IBA21873635  
GO:0005634nucleus-ISS-  
GO:0005654nucleoplasm-TAS-  
GO:0005737cytoplasm-IBA21873635  
GO:0005737cytoplasm-IDA17244647  
GO:0005829cytosol-TAS-  
KEGG ID KEGG Term
hsa04310Wnt signaling pathway
hsa04340Hedgehog signaling pathway
hsa04710Circadian rhythm
Reactome ID Reactome Term Evidence
R-HSA-162582Signal TransductionTAS
R-HSA-1640170Cell CycleTAS
R-HSA-1852241Organelle biogenesis and maintenanceTAS
R-HSA-195721Signaling by WNTTAS
R-HSA-201681TCF dependent signaling in response to WNTTAS
R-HSA-201688WNT mediated activation of DVLTAS
R-HSA-2565942Regulation of PLK1 Activity at G2/M TransitionTAS
R-HSA-380259Loss of Nlp from mitotic centrosomesTAS
R-HSA-380270Recruitment of mitotic centrosome proteins and complexesTAS
R-HSA-380284Loss of proteins required for interphase microtubule organization from the centrosomeTAS
R-HSA-380287Centrosome maturationTAS
R-HSA-380320Recruitment of NuMA to mitotic centrosomesTAS
R-HSA-400253Circadian ClockIEA
R-HSA-453274Mitotic G2-G2/M phasesTAS
R-HSA-5617833Cilium AssemblyTAS
R-HSA-5620912Anchoring of the basal body to the plasma membraneTAS
R-HSA-6791226Major pathway of rRNA processing in the nucleolus and cytosolTAS
R-HSA-68877Mitotic PrometaphaseTAS
R-HSA-68886M PhaseTAS
R-HSA-69275G2/M TransitionTAS
R-HSA-69278Cell Cycle, MitoticTAS
R-HSA-72312rRNA processingTAS
R-HSA-8854518AURKA Activation by TPX2TAS
R-HSA-8868773rRNA processing in the nucleus and cytosolTAS
R-HSA-8953854Metabolism of RNATAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
25187986Nightshift work and genome-wide DNA methylation. (2015 Feb)Bhatti PChronobiol Int
28296937Effects of circadian clock genes and health-related behavior on metabolic syndrome in a Taiwanese population: Evidence from association and interaction analysis. (2017)Lin EPLoS One
25875614Overlapping dopaminergic pathway genetic susceptibility to heroin and cocaine addictions in African Americans. (2015 May)Levran OAnn Hum Genet